The denominator in early phase CAR T-cell trials examining novel taret antigens
Last Updated: Friday, August 18, 2023
This commentary by Muhammad Bilal Abid discusses the need for patient-centric endpoints in early-phase clinical trials examining lymphoid malignancies, and these trials should be more inclusive of patients with high-risk disease and more transparent in toxicity reporting.
Advertisement
News & Literature Highlights